Lead Product(s) : Brepocitinib
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Priovant Receives Fast Track Designation for Brepocitinib and Start of Phase 3
Details : PF-06700841 (brepocitinib) is a novel small molecule TYK2/JAK1 inhibitor which is being evaluated for the treatment of patients with non-anterior non-infectious uveitis.
Product Name : PF-06700841
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 23, 2024
Lead Product(s) : Brepocitinib
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Brepocitinib
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Roivant Reports NEPTUNE Study Success for Brepocitinib in NIU; $1.5 Bn Buyback Approved
Details : PF-06700841 (brepocitinib) is a novel small molecule TYK2/JAK1 inhibitor which is being evaluated for the treatment of patients with non-anterior non-infectious uveitis.
Product Name : PF-06700841
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 04, 2024
Lead Product(s) : Brepocitinib
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Brepocitinib
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PF-06700841 (brepocitinib) is a novel small molecule TYK2/JAK1 inhibitor which is being evaluated for the treatment of patients with systemic lupus erythematosus.
Product Name : PF-06700841
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 27, 2023
Lead Product(s) : Brepocitinib
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Brepocitinib
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PF-06700841 (brepocitinib) is a potential first-in-class dual, selective inhibitor of TYK2 and JAK1; in all five placebo-controlled studies completed to date, oral brepocitinib generated statistically significant and clinically meaningful results.
Product Name : PF-06700841
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 28, 2022
Lead Product(s) : Brepocitinib
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable